Selective HDAC1 and HDAC2 Inhibitors for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for structurally diverse and potent selective inhibitors of histone deacetylase (HDAC) enzymes, particularly for HDAC1 and HDAC2, to effectively treat diseases such as cancer, sickle-cell anemia, beta-thalassemia, and HIV, as current HDAC inhibitors are non-specific and have off-target side effects.
Innovation Solution
Development of specific compounds, such as those represented by Formulas I, II, and III, and listed in Table 1, which selectively inhibit HDAC1 and HDAC2 with a selectivity of 5 to 1000-fold greater than other HDACs, allowing for targeted therapeutic approaches for various diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific HDAC inhibitors are used, then broad HDAC inhibition is achieved, but off-target side effects increase
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features (hydroxamic acid group combined with particular heterocyclic structures) that selectively interact with the catalytic pocket of HDAC1 and HDAC2, while lacking the structural properties needed to inhibit other HDAC isoforms. This localized molecular design achieves selective inhibition at the target site without affecting other enzymes.
Solution Approach 2:
The patent employs parameter changes by systematically varying key molecular parameters of the inhibitor structures (such as the heterocyclic ring type, substituent positions, and hydroxamic acid derivatives) to optimize selectivity for HDAC1/HDAC2. By adjusting these chemical parameters, the inhibitors achieve 5-1000 fold greater potency against HDAC1/2 compared to other HDAC isoforms.
2Manufacturing precision
If selective HDAC1/HDAC2 inhibitors are developed, then therapeutic precision is improved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a heterocyclic core structure (providing structural diversity and target recognition), a linker region, and a hydroxamic acid group (providing zinc-binding capability). This modular segmentation allows independent optimization of each component for selectivity while maintaining overall structural manageability.
Solution Approach 2:
The patent employs composite materials by combining different heterocyclic frameworks (pyridine, pyrimidine, triazine rings) with hydroxamic acid moieties to create composite molecular structures. These composite compounds leverage the complementary properties of each component to achieve high selectivity for HDAC1/2 while maintaining synthetic accessibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate potent inhibition of HDAC1 and HDAC2, achieving selective inhibition with minimal cytotoxicity, thereby providing a refined therapeutic strategy for treating HDAC-related diseases, including cancer and HIV, with improved efficacy and reduced side effects.
Implementation Method 1
HDACs are zinc hydrolases that modulate gene expression through deacetylation of the N-acetyl-lysine residues of histone proteins... compounds... selectively inhibit HDAC1 and HDAC2
Data Source
AI summary
Provided herein are compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1 and/or HDAC2. Such diseases include cancer, sickle-cell anemia, beta-thalassemia, and HIV.